News Background

Oxford, UK – 10 June 2010. OGT, provider of innovative genetics and biomarker solutions to advance molecular medicine, today announced that its CytoSure® Interpret Software can now seamlessly transfer array comparative genomic hybridization (aCGH) aberration data directly to Cartagenia’s Bench™ constitutional cytogenetics platform. This helps cytogeneticists accurately correlate genotypic findings with known clinical phenotypes. Further details of this new functionality will be presented in two workshops at the European Human Genetics Conference 2010 in Gothenburg, Sweden, 12-15 June. On 12 June, OGT will present “From disease to cytogenetics research – An integrated CNV analysis platform from Oxford Gene Technology” at 12.00 in room H1. Following on from this at 14.00 in room R4, Cartagenia will present “Routine clinical interpretation of copy number variation".

With the ability to automatically detect CNV aberrations, CytoSure Interpret Software generates reliable and reproducible results, which can be cross referenced with external aberration databases for accurate data interpretation. These results can now be effortlessly transferred to Cartagenia’s Bench platform, allowing additional data management options — including quick and secure data sharing within, and across, various research facilities — and support for genotypephenotype correlation analysis.

OGT and Cartagenia will be exhibiting at ESHG 2010 on booths B-550 and B-632 respectively.

About OGT

OGT, a Sysmex Group company, is a leading global provider of clinical and diagnostic genomic solutions that are created for scientists by scientists - including CytoCell®, CytoSure® and SureSeq™ ranges of FISH, microarray and NGS products. The company is dedicated to creating products that enable researchers and clinical decision makers to reach the right care decisions for each patient, every time. OGT strives to unlock the future of genetic clinical care with a commitment to working in partnership with its customers - not only by sharing its expertise of 25 years at the forefront of genetic endeavour, but also by working closely with scientists to understand their unique challenges, and to customise its approach to meet their exact needs. Dedicated to improving clinical care, OGT believes that through partnership—together—we’ll achieve more.

 

For more information on the Company, please visit our website at ogt.com

 

CytoSure®, SureSeq™ and myProbes®: For Research Use Only, not for use in diagnostic procedures. CytoCell: Some products may not be available in your region.

 

About Sysmex Corporation

Sysmex Corporation is a world leader in clinical laboratory systemization and solutions, including laboratory diagnostics, laboratory automation and clinical information systems. Serving customers for more than 50 years, Sysmex focuses on technological leadership in diagnostic science and information tools that make a difference in the health of people worldwide. The company is also exploring emerging opportunities in the life science field. Its R&D efforts focus on the development of high-value-added testing and diagnostic technologies that are innovative, original and optimize individual health. Sysmex also seeks to leverage its state-of-the-art technologies for cell, gene and protein analysis. The company, headquartered in Kobe, Japan, has subsidiaries in North America, Latin America, Europe, the Middle East, Africa, China and Asia Pacific and employs more than 9,000 employees worldwide. Sysmex Corporation is listed in the top tier of the Tokyo Stock Exchange.

 

For more information about Sysmex Corporation and its affiliate companies, please visit www.sysmex.co.jp/en/.

Related content

  • Share

You might also be interested in

NGS Cytosure NGS Product Packaging

OGT develops transformative constitutional NGS panel

10 Dec 2019

CytoSure® NGS – Combining the benefits of microarrays and NGS in a single assay.

Read
MDSAP

OGT continues move into molecular diagnostics markets

18 Nov 2019

MDSAP certification of new Cambridge facility smooths path to future IVD approvals.

Read
NGS Scientist And Interpret Software

OGT launches breakthrough NGS panel for constitutional cytogenetics

30 Jan 2020

Robust panel enables accurate and comprehensive constitutional genetic aberration screening in one assay.

Read
All News
CTA Icon

Stay up-to-date with the latest news from OGT, including new products, support resources, and our DNA Dispatch newsletter